NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax Corporate Headquarters and Laboratory Relocation
TL;DR
GeoVax's relocation to Atlanta's bio-ecosystem positions the company for accelerated growth and market readiness in cancer and infectious disease therapies.
GeoVax is moving its R&D to Science Square's modern labs and corporate headquarters to Smyrna, supporting pipeline expansion and product commercialization in Q4 2025.
GeoVax's enhanced facilities will advance cancer and infectious disease treatments, potentially improving global healthcare outcomes for immunocompromised patients and others.
GeoVax joins Atlanta's dynamic bio-research hub at Science Square, accelerating innovation in vaccines and cancer therapies through collaborative environments.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax is relocating both its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area to support the company's continued growth, expanding pipeline, and preparation for product commercialization.
The moves are scheduled for the fourth quarter of 2025.
The laboratory group is moving to Science Square / Portal Innovations in midtown Atlanta, while the corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia.
The moves position GeoVax for accelerated growth, provide expanded access to modern laboratories and collaborative research environments, and strengthen ties to Georgia's bio-ecosystem to support late-stage development and market readiness.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that these moves reflect a significant milestone in the company's evolution and will support their broad and advancing pipeline.
The Science Square / Portal Innovations facility will provide GeoVax's R&D team with expanded access to state-of-the-art laboratories and collaborative research environments designed to accelerate innovation and development activities.
Portal Innovations is an innovation engine that supports scientific companies including life sciences and biotech in all stages of development, and Eddie Lai, Director of Business Development for Atlanta Portal Innovations, expressed excitement about GeoVax joining their ecosystem.
The relocations underscore GeoVax's trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities, providing a strong foundation to meet global healthcare needs.
GeoVax's pipeline includes the GEO-MVA program, GEO-CM04S1 (a next-generation COVID-19 vaccine in Phase 2 trials), Gedeptin® (an oncolytic solid tumor therapy), and a vaccine targeting Mpox and smallpox.
Curated from NewMediaWire
